Peter K Law

Peter K Law
Cell Therapy Institute , Wuhan, CHINA · Regenerative Medicine

Professor
1. Myoblast Transfer Therapies in clinical trials of DMD, heart failure, cancer, aging 2. COVID-19 Origin and Treatment

About

108
Publications
134,203
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
2,078
Citations
Citations since 2017
14 Research Items
340 Citations
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
Introduction
Myoblast Transplantation in treating muscular dystrophies, heart failure, ischemic cardiomyopathy, Type II diabetes, cancer, and aging disfigurement. Convalescent Serum Transfusion Therapy in treating COVIID-19.

Publications

Publications (108)
Preprint
Full-text available
This review presents direct, unequivocal evidence to indicate that the US Government under Donald Trump had used genetically engineered bioweapon of coronavirus and HIV recombinant to plunder the lives of over 5 million innocent people and trillions USD worth of equity and natural resources with more to come. Evidence are based on facts, events and...
Chapter
Full-text available
Intramuscular implantation of cultured allogeneic myoblasts derived from pathogen-free muscle biopsies of genetically normal human volunteers demonstrated safety and efficacy in clinical studies of Duchenne muscular dystrophy (DMD), heart failure, ischemic cardiomyopathy, Type-II diabetes, cancer and aging disfigurement. Through natural cell fusion...
Article
Full-text available
The science behind two life-saving protocols to combat COVID-19 and future pathogenic epidemics is presented for immediate implementation.
Chapter
Full-text available
Intramuscular implantation of cultured allogeneic myoblasts derived from pathogen-free muscle biopsies of genetically normal human volunteers demonstrated safety and efficacy in clinical studies of Duchenne muscular dystrophy (DMD), heart failure, ischemic cardiomyopathy, Type-II diabetes, cancer, and aging disfigurement. Through natural cell fusio...
Article
Full-text available
Clinical trial on DMD with myoblast transplantation
Experiment Findings
Full-text available
In this review, Hoffman consistently quotes opin ions as factual, be those of the press, his own, or his colleagues. Pioneering animal (10) and human (8) stud ies on MTT from several laboratories were discredited or not referenced, whereas his associate Partridge was promoted as "the leader in this field." The significance of dystrophin may be over...
Article
Full-text available
This review presents direct, unequivocal evidence to indicate that the US Government under Donald Trump had used genetically engineered bioweapon of coronavirus and HIV recombinant to plunder the lives of over 5 million innocent people and trillions USD worth of equity and natural resources with more to come. Evidence are based on facts, events and...
Article
Full-text available
Remote and robotically actuated catheters are the stepping-stones toward autonomous catheters, where complex intravascular procedures may be performed with minimal intervention from a physician. This article proposes a concept for the positional, feedforward control of a robotically actuated cell injection catheter used for the injection of myogeni...
Article
Full-text available
This article discusses existing catheter systems and proposes a conceptual design and procedure for an autonomous cellinjection catheter for the purpose of transferring committed myogenic or undifferentiated stem cells into the infarct boundary zones of the left ventricle. Operation of existing catheters used for cell delivery is far from optimal....
Article
Full-text available
This paper provides an overview of the conventional therapeutic stimulation methodologies and proposes a more effective stimulation approach based on a consideration of the inherently fractal nature of normal biological dynamics. There are varying forms of physiological stimulations including the use of electrical currents, electromagnetic fields,...
Article
Full-text available
The study aims to investigate the gene expression profiling of insulin signaling pathway and mitochondrial biogenesis and function in the skeletal muscle of KK mice. KK mice were divided into the following groups: KK control group, basal medium (M199) only; KK fibroblast group, with human fibroblast transplantation; KK myoblast group, with human sk...
Article
Massive cell death associated with poor donor cell survival was a limiting factor in the success of myoblast transfer therapy (MTT). The current study is aimed to determine the effects of thymosin β4 on human skeletal myoblast (hSkM) migration, proliferation and survival under hypoxia. hSkM was cultured in basal medium (BM, M199 medium with 10% fet...
Article
This article reviews the scientific and intellectual property development of a biotechnology platform in regenerative medicine called Human Myoblast Genome Therapy (HMGT), known previously as Myoblast Transfer Therapy (MTT). Myoblasts are the least differentiated myogenic cells capable of extensive division, natural cell fusion, nucleus transfer, c...
Article
Full-text available
We aimed to demonstrate the feasibility and efficacy of intra-muscular transplantation of human skeletal myoblasts (hSkMs) for attenuation of hyperglycaemia and improvement of insulin sensitivity using a mouse model of type 2 diabetes mellitus. KK Cg-Ay/J mice, aged 12 to 14 weeks, underwent an initial intraperitoneal glucose tolerance test (GTT) a...
Article
The study aims to use cholesterol (Chol) + DOTAP liposome (CD liposome) based human vascular endothelial growth factor-165 (VEGF(165)) gene transfer into skeletal myoblasts (SkMs) for treatment of acute hind limb ischaemia in a rabbit model. The feasibility and efficacy of CD liposome mediated gene transfer with rabbit SkMs were characterized using...
Article
Full-text available
We aim to investigate the feasibility and efficacy of cholesterol (Chol)+DOTAP liposome (CD liposome) based human vascular endothelial growth factor-165 (hVEGF(165)) gene transfer into human skeletal myoblasts (hSkM) for cardiac repair. The feasibility and efficacy of CD liposome for gene transfer with hSkM was characterized using plasmid carrying...
Article
Low-level transgene efficiency is one of the main obstacles in ex vivo nonviral vector-mediated gene transfer into primary human skeletal myoblasts (hSkMs). We optimized the cholesterol:N-[1-(2, 3-dioleoyloxy)propyl]-N, N, N-trimethylammonium methylsulfate liposome (CD liposome) and 22-kDa polyethylenimine (PEI22)- and 25-kDa polyethylenimine (PEI2...
Article
Full-text available
We sought to investigate immune cell kinetics in relation to skeletal myoblast survival and heart function improvement after nonautologous skeletal myoblast transplantation in a rat model of myocardial infarction. One week after myocardial infarction, 208 Wistar rats were grouped into group 1 (n = 24, receiving 150 muL of medium only), group 2 (n =...
Article
We investigated the feasibility and efficacy of polyethylenimine (PEI) based human vascular endothelial growth factor-165 (hVEGF165) gene transfer into human skeletal myoblasts (HSM) for cell based delivery to the infarcted myocardium. Based on optimized transfection procedure using enhanced green fluorescent protein (pEGFP), HSM were transfected w...
Article
To achieve angiogenic interaction between VEGF(165) and angiopoietin-1 (Ang-1) using a novel adenoviral bicistronic vector (Ad-Bic) encoding the two factors and delivered ex vivo using sex-mismatched human skeletal myoblasts. A myocardial infarction model was developed in 29 female pigs; randomised into four groups: DMEM (group-1, n=6); Adenovirus...
Article
Full-text available
Objectives: This study investigated the efficacy of human skeletal myoblasts (SkM) mediated either human vascular endothelial growth factor-165 (hVEGF165) or angiopoietin-1 (Ang-1) on vascular development and myocardial regional perfusion. Methods: A porcine heart model of chronic infarction was created in 28 female swine by coronary artery ligatio...
Article
Full-text available
Human Myoblast Genome Therapy (HMGT) is a platform technology of cell transplantation, nuclear transfer, and tissue engineering. Unlike stem cells, myoblasts are differentiated, immature cells destined to become muscles. Myoblasts cultured from satellite cells of adult muscle biopsies survive, develop, and function to revitalize degenerative muscle...
Article
We hypothesized that combination therapy using human myoblasts and VEGF165 will lead to better prognosis in a failing heart. Forty-eight female Wistar rats with cryoinjured hearts were randomized into non-treated normal (group-1, n=12), DMEM injected (group-2, n=10), myoblast-transplanted (group-3, n=12) and myoblast-hVEGF(165) (group-4, n=14). Ten...
Article
Full-text available
We report in vitro functional assessment of human skeletal myoblasts with adenoviral bicistronic vector carrying human vascular endothelial growth factor-165 (hVEGF165) and angiopoietin-1 (Ang-1). Myoblasts were assessed for their purity by desmin expression. A replication incompetent adenoviral bicistronic vector (Ad-Bic) carrying both hVEGF165 an...
Article
Full-text available
Cellular cardiomyoplasty using various types of donor cells is now validated by a large number of experimental studies. We report a case of cellular cardiomyoplasty performed on a beating heart using autologous skeletal myoblasts, thus combining the efficacy of both procedures. Approximately 2.5 g of rectus femoris muscle tissue biopsy was taken fr...
Article
Full-text available
Bioengineering the regenerative heart may provide a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering from ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. As on August 28, 2002, his EKG was normal and show...
Article
Full-text available
This study investigated the potential of human skeletal myoblast carrying human VEGF(165) for angiomyogenesis for cardiac repair. A porcine heart model of chronic infarction was created in 18 female swine by coronary artery ligation. The animals were randomized into: group 1, DMEM injected ( n=6), group 2, myoblast transplanted ( n=5) and group 3,...
Article
Full-text available
We studied the survival of human myoblast for cellular myocardial reconstruction in a porcine model of chronic myocardial ischemia with immune tolerance using transient immunosuppression. A porcine model of chronic cardiac ischemia was created in 10 pigs (DMEM medium-injected n = 4; myoblast transplanted n = 6) by clamping ameroid ring around left...
Article
Full-text available
We report the transduction of human VEGF165 gene into human myoblast and characterization of the transduced myoblasts for transduction and expression efficiency. Human myoblasts were assessed by immunostaining for desmin expression. A replication incompetent adenoviral vector carrying human VEGF165 was constructed and used for transduction of myobl...
Article
Full-text available
Myoblast transplant for cardiac repair offers an alternative therapeutic modality for cardiac repair. This novel cell based approach has the potential for replacing cardiomyocytes damaged during the disease process. Studies in the small and large animals and human phase-I trials have shown that myoblast transplantation into damaged myocardium resul...
Article
Full-text available
Aim: Considering the promise of skeletal myoblast cell transplantation to improve cardiac function in myocardial myopathies, we aim in the present study to investigate the potential of human skeletal myoblast cells (HSMC) as a carrier for therapeutic genes for the heart muscle. Methods: Skeletal muscle sample is obtained from rectus femoris of the...
Article
Full-text available
Summary Myoblasts divide profusely, and fuse during muscle regeneration, interiorizing MHC-I antigens and inserting myonuclei with the normal genome into muscles of genetically deficient recipients, where any replacement gene can be stably integrated and naturally expressed. Myoblasts are the natural source and vehicle for many gene therapies. Myob...
Article
Full-text available
Article
Full-text available
The feasibility, safety, and efficacy of myoblast transfer therapy (MIT) were assessed in an experimental lower body treatment (LBT) involving 32 Duchenne muscular dystrophy (DMD) boys aged 6-14 yr, half of whom were nonambulatory. Through 48 injections, five billion (55.6 x 10(6)/mL) normal myoblasts were transferred into 22 major muscles in both...
Article
Full-text available
Article
Full-text available
Five billion normal myoblasts were injected into each of 21 Duchenne muscular dystrophy (DMD) boys aged 6-14 yr to assess the feasibility, safety, and efficacy of the Phase II myoblast transfer therapy (MTT). The Phase II study was designed to strengthen muscles of both lower limbs. Forty-eight intramuscular injections transferred the myoblasts int...
Article
Full-text available
A new technique enables correlation of dystrophin expression with the location of donor versus host nuclei in the same sections of mdx mouse muscle injected with normal myoblasts. Myoblasts from C57BL/6J mice or from humans were labeled with 0.01% fluoro-gold (FG) in Dulbecco's Modified Eagles Medium (DMEM) for 16 h at 37 degrees C before myoblast...
Article
Full-text available
Five billion normal myoblasts were injected into each of 21 Duchenne muscular dystrophy (DMD) boys aged 6-14 yr to assess the feasibility, safety, and efficacy of the Phase II myoblast transfer therapy (MTT). The Phase II study was designed to strengthen muscles of both lower limbs. Forty-eight intramuscular injections transferred the myoblasts int...
Article
Full-text available
A randomly selected extensor digitorum brevis (EDB) muscle in each of three Duchenne muscular dystrophy (DMD) boys aged 9 to 10 was injected with approximately 8 x 10(6) myoblasts. The contralateral EDBs were sham-injected with carrier solution. Donor myoblasts were derived from cell culture of muscle biopsies from the normal ward or normal brother...
Article
A new method is developed using Fluoro-Gold (FG) as a vital stain to label the nuclei of donor myoblasts in myoblast transfer studies. In vitro incubation with 0.01% FG for 16 h resulted in 100% nuclei labelling. Intensive fluorescence persisted following 9 days of subculture, when the human myoblasts were injected into the quadriceps of mouse reci...
Article
Full-text available
As of April 7, the Institutional Review Board has approved our proposal on human trial with myoblast transfer therapy.
Article
Full-text available
Dystrophic cells degenerate because they lack the normal genome. In our laboratory, transplant techniques have been developed to facilitate cell survival and cell fusion, such that the normal genome can be incorporated back into the dystrophic muscle1–6.
Article
Full-text available
A treatment has been developed to alleviate muscle weakness in murine dystrophy. Cultured myoblasts from genetically normal mouse embryos were injected into the right soleus of 20-day-old normal or dystrophic mice. Hosts and donors were immunocompatible but exhibited different genotype markers. Donor cells produced GPl-1CC. Host cells produced GPl-...
Article
Full-text available
Measurements of [1-14C]oleoyl CoA oxidation in homogenates and isolated mitochondria of skeletal muscles, hearts and livers from dystrophic C57BL/6J mice and unaffected litter-mates indicate that rates are lower in dystrophic mitochondria, but are comparable in whole homogenates. These findings are not due to differences in the endogenous concentra...